Polycythemia vera, a rare blood cancer characterized by the overproduction of red blood cells, now has its first FDA-approved drug treatment. The agency awarded the regulatory nod to a PharmaEssentia drug that reduces the levels of those blood cells.
In exchange for ceding rights to develop, sell and market Akili's two lead products in Japan and Taiwan to Shionogi, Akili will receive $20 million upfront and up to $105 million in additional payments dependent on reaching certain development and commercial milestones.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Through the deal Health2Sync will work with Novo Nordisk to market and localize the company's patient management tool and SyncHealth app, which nudges users towards timely healthy behaviors around exercise, diet and blood glucose management.
WI Harper, Cherubic Ventures, iSeed Ventures, and SparkLabs Global Ventures took part in the funding round.
When one out of every six couples has trouble conceiving, a new iPad device could make it easier to examine where the problem could be.
A Bay Area startup is harnessing the haute monoclonal antibody technology to develop treatment for psoriasis, cancers and inflammatory disease, and is likely about to kick off some serious late-stage efficacy trials. AbGenomics is in the midst of a $24.5 million fundraising round, according to regulatory filings, and has raised $13.2 million to date. The company […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.